MedTrace Logo

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT04513821 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-08-14

No results posted yet for this study

Summary

This is an Intermediate-Size Expanded Access, Open-Label Study for Use of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Central Line Associated Bloodstream Infection. Mino-Lok may be made available for patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717 )

Conditions

  • Catheter-Related Infections

Interventions

DRUG

Mino-Lok Therapy (MLT)

Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok

Sponsors & Collaborators

  • Leonard-Meron Biosciences, Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513821 on ClinicalTrials.gov